Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06907251
PHASE3

Dapagliflozin for Long COVID Syndrome

Sponsor: Ottawa Heart Institute Research Corporation

View on ClinicalTrials.gov

Summary

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

192

Start Date

2026-04-01

Completion Date

2029-06-30

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DRUG

Dapagliflozin (DAPA)

Dapagliflozin 10mg orally once a day for 12 months

DRUG

Placebo

Participants will receive a matching placebo taken once daily by mouth for 12 months.

Locations (1)

University of Ottawa Heart Institute

Ottawa, Ontario, Canada